Ablove T, et al. - The effectiveness of the muscarinic receptor antagonist solifenacin (VESIcare) in the treatment of postvoid dribbling (PVD) was determined. In this work, the solifenacin and placebo groups showed no differences in PVD outcomes. Subgroup analysis, based on those with more severe disease (>10 PVD episodes/week), demonstrated a greater and significant percentage reduction in the frequency of PVD episodes per day and a higher percentage of patients showing ≥50% reduction in the frequency of PVD episodes with solifenacin. As this study demonstrated powerful placebo response, behavior-based interventions could be of value for treating PVD.